Craniopharyngioma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CRN036 MIFTS: 62	Craniopharyngioma Categories: Cancer diseases, Endocrine diseases, Eye diseases, Neuronal diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Craniopharyngioma

MalaCards integrated aliases for Craniopharyngioma:

Name: Craniopharyngioma ¹¹ ¹⁹ ⁵⁸ ⁵³ ⁵ ⁴³ ¹⁴ ¹⁶ ⁷¹ ⁷⁵

Dysodontogenic Epithelial Tumor ¹⁹

Craniopharyngeal Duct Tumor ¹⁹

Neoplasm of Rathke's Pouch ¹¹

Adamantinomatous Tumor ¹⁹

Rathke's Pouch Tumor ¹⁹

Characteristics:

Prevelance:

1-9/100000 (Europe) 1-9/1000000 (United States, Sweden) ⁵⁸

Age Of Onset:

All ages ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases Endocrine diseases Eye diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Neoplasms

Neoplasms of uncertain or unknown behaviour

Neoplasm of uncertain or unknown behaviour of endocrine glands

Neoplasm of uncertain or unknown behaviour: Craniopharyngeal duct

Orphanet: ⁵⁸

Rare neurological diseases

Rare endocrine diseases

Sources

Summaries for Craniopharyngioma

GARD: ¹⁹ Craniopharyngioma is a slow-growing, non-cancerous brain tumor that develops near the pituitary gland (a small endocrine gland at the base of the brain which produces several important hormones) and the hypothalamus (an endocrine organ which controls the release of hormones by the pituitary gland). Although Craniopharyngiomas are not cancerous, they may grow and press on nearby parts of the brain, causing symptoms including hormonal changes, vision changes, slow growth, headaches, nausea and vomiting, loss of balance, hearing loss, and changes in mood or behavior. The cause of these tumors is not well understood.

MalaCards based summary: Craniopharyngioma, also known as dysodontogenic epithelial tumor, is related to papillary craniopharyngioma and adamantinous craniopharyngioma, and has symptoms including visual disturbance An important gene associated with Craniopharyngioma is APC (APC Regulator Of WNT Signaling Pathway), and among its related pathways/superpathways are Signal Transduction and Nanog in Mammalian ESC Pluripotency. The drugs Prednisone and Hydrocortisone succinate have been mentioned in the context of this disorder. Affiliated tissues include pituitary, hypothalamus and brain, and related phenotypes are abnormal hypothalamus morphology and cerebral calcification

Orphanet: ⁵⁸ Craniopharyngiomas are benign slow growing tumours that are located within the sellar and parasellar regions of the central nervous system.

Wikipedia: ⁷⁵ A craniopharyngioma is a rare type of brain tumor derived from pituitary gland embryonic tissue that... more...

Sources

Related Diseases for Craniopharyngioma

Diseases related to Craniopharyngioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 621)

#	Related Disease	Score	Top Affiliating Genes
1	papillary craniopharyngioma	32.8	KRT7 CTNNB1 BRAF
2	adamantinous craniopharyngioma	32.1	SOX2 PROP1 LEF1 CTNNB1
3	central diabetes insipidus	31.3	TRH PRL IGF1 GNRH1
4	leptin deficiency or dysfunction	31.0	TRH LEPR INS IL6 IGF1 GNRH1
5	ameloblastoma	30.9	KRT8 KRT14 CTNNB1
6	eating disorder	30.8	LEPR INS IGF1 GHRL
7	pituitary adenoma	30.8	TRH PRL POU1F1 IGF1 GNRH1 GHRL
8	adult syndrome	30.8	INS IL6 IGF1
9	sleep disorder	30.8	INS IL6 IGF1 GHRL
10	hyperinsulinism	30.7	LEPR INS IGF1 GNRH1 GHRL
11	abdominal obesity-metabolic syndrome 1	30.6	LEPR INS GHRL
12	apnea, obstructive sleep	30.6	INS IL6 IGF1 GHRL
13	adenoma	30.6	TRH PRL POU1F1 KRT7 IGF1 CTNNB1
14	pilomatrixoma	30.5	LEF1 KRT14 CTNNB1
15	galactorrhea	30.5	PRL IGF1
16	fatty liver disease	30.5	LEPR INS IL6 IGF1 GHRL
17	hyperprolactinemia	30.5	TRH PRL INS IGF1 GNRH1
18	lipid metabolism disorder	30.4	LEPR INS IL6 IGF1 GHRL
19	teratoma	30.4	SOX2 KRT7 INS CTNNB1
20	amenorrhea	30.4	TRH PRL INS IGF1 GNRH1 GHRL
21	pituitary hormone deficiency, combined, 2	30.4	TRH PROP1 PRL POU1F1 IGF1 GNRH1
22	sleep apnea	30.4	LEPR INS IL6 IGF1 GHRL
23	prediabetes syndrome	30.3	LEPR INS IGF1 GHRL
24	hypoglycemia	30.3	TRH PRL INS IGF1 GHRL
25	body mass index quantitative trait locus 11	30.3	TRH PRL LEPR INS IL6 IGF1
26	functioning pituitary adenoma	30.2	TRH PRL POU1F1 IGF1
27	insulin-like growth factor i	30.2	PRL INS IL6 IGF1 GHRL
28	type 1 diabetes mellitus	30.2	LEPR INS IL6 IGF1 GHRL
29	pituitary tumors	30.2	PROP1 PRL IGF1
30	hypopituitarism	30.2	TRH SOX2 PROP1 PRL POU1F1 INS
31	chromophobe adenoma	30.2	TRH PRL
32	liver cirrhosis	30.1	LEPR KRT8 INS IL6
33	isolated growth hormone deficiency	30.1	PROP1 POU1F1 IGF1
34	pituitary apoplexy	30.1	TRH PRL INS IL6 IGF1 GNRH1
35	thyroiditis	30.0	PRL INS IL6
36	hypothalamic disease	30.0	TRH PRL INS IGF1 GNRH1
37	celiac disease 1	30.0	INS IL6 IGF1 GHRL
38	pituitary gland disease	30.0	TRH PROP1 PRL POU1F1 INS IGF1
39	anorexia nervosa	30.0	PRL LEPR INS IGF1 GHRL
40	hypogonadism	30.0	PROP1 PRL LEPR INS IGF1 GNRH1
41	prolactinoma	29.8	TRH PRL POU1F1 INS IGF1 GNRH1
42	acromegaly	29.8	TRH PRL INS IGF1 GNRH1 GHRL
43	conn's syndrome	29.8	TRH PRL INS IL6 IGF1 GNRH1
44	prader-willi syndrome	29.7	TRH PRL LEPR INS IL6 IGF1
45	major depressive disorder	29.7	TRH PRL INS IL6 GHRL
46	hypothyroidism	29.7	TRH PROP1 PRL POU1F1 INS IGF1
47	hyperthyroidism	29.7	TRH PRL INS IL6 IGF1 GHRL
48	fibrous dysplasia	29.7	PRL IL6 IGF1 APC
49	alopecia	29.6	PRL KRT14 IL6 IGF1 CTNNB1
50	basal cell carcinoma	29.6	KRT8 KRT7 KRT14 IL6 ERCC2 CTNNB1

Graphical network of the top 20 diseases related to Craniopharyngioma:

Sources

Symptoms & Phenotypes for Craniopharyngioma

Human phenotypes related to Craniopharyngioma:

⁵⁸ ³⁰ (show all 49)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	abnormal hypothalamus morphology ⁵⁸ ³⁰	Obligate (100%)	Obligate (100%)	HP:0012286
2	cerebral calcification ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002514
3	enlarged pituitary gland ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0012505
4	intracranial cystic lesion ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0010576
5	neoplasm of the anterior pituitary ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0011750
6	nausea and vomiting ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002017
7	obesity ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001513
8	headache ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002315
9	excessive daytime somnolence ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001262
10	pituitary hypothyroidism ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0008245
11	central diabetes insipidus ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000863
12	central adrenal insufficiency ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0011734
13	bitemporal hemianopia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0030521
14	increased circulating prolactin concentration ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000870
15	progressive visual field defects ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0007987
16	abnormal visual field test ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0030588
17	papilledema ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001085
18	slow decrease in visual acuity ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0007924
19	hypogonadotropic hypogonadism ³⁰	Frequent (33%)		HP:0000044
20	sleep apnea ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0010535
21	hydrocephalus ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000238
22	hearing impairment ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000365
23	type ii diabetes mellitus ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0005978
24	increased intracranial pressure ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002516
25	optic atrophy ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000648
26	delayed puberty ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000823
27	cerebral ischemia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002637
28	increased susceptibility to fractures ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002659
29	polyphagia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002591
30	proportionate short stature ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0003508
31	intellectual disability ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0001249
32	seizure ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0001250
33	global developmental delay ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0001263
34	postnatal growth retardation ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0008897
35	myocardial infarction ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0001658
36	vertigo ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0002321
37	recurrent infections ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0002719
38	coma ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0001259
39	sudden loss of visual acuity ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0001117
40	abnormal nasal bone morphology ³⁰	Very rare (1%)		HP:0010939
41	abnormal frontal bone morphology ³⁰	Very rare (1%)		HP:0430000
42	sleep disturbance ⁵⁸		Frequent (79-30%)
43	behavioral abnormality ⁵⁸		Very rare (<4-1%)
44	growth delay ⁵⁸		Occasional (29-5%)
45	hypogonadism ⁵⁸		Frequent (79-30%)
46	low gonadotropins (secondary hypogonadism) ⁵⁸		Frequent (79-30%)
47	hypopituitarism ⁵⁸		Very frequent (99-80%)
48	abnormality of the nasal bone ⁵⁸		Very rare (<4-1%)
49	abnormality of the frontal bone ⁵⁸		Very rare (<4-1%)

UMLS symptoms related to Craniopharyngioma:

visual disturbance

GenomeRNAi Phenotypes related to Craniopharyngioma according to GeneCards Suite gene sharing:

²⁵ (show all 15)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.19	APC BRAF CTNNB1 ERCC2 GHRL GNRH1
2	no effect	GR00402-S-2	10.19	APC BRAF CTNNB1 ERCC2 GHRL GNRH1
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-126	10.15	KRT8
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-133	10.15	APC
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-135	10.15	KRT7 KRT8
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-180	10.15	KRT8
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-192	10.15	APC KRT7 KRT8
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-202	10.15	APC
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-40	10.15	KRT8
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-47	10.15	CTNNB1
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-68	10.15	KRT7
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-72	10.15	KRT7
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-74	10.15	KRT7 KRT8
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-91	10.15	KRT7
15	Decreased viability in pancreas lineage	GR00235-A	8.85	KRT7

MGI Mouse Phenotypes related to Craniopharyngioma:

⁴⁵ (show all 25)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.52	APC BRAF CTNNB1 ERCC2 GHRL GNRH1
2	nervous system	MP:0003631	10.51	APC BRAF CTNNB1 ERCC2 GNRH1 IGF1
3	growth/size/body region	MP:0005378	10.48	APC BRAF CTNNB1 ERCC2 GNRH1 IGF1
4	endocrine/exocrine gland	MP:0005379	10.47	APC BRAF CTNNB1 ERCC2 GHRL GNRH1
5	neoplasm	MP:0002006	10.4	APC BRAF CTNNB1 ERCC2 GNRH1 IGF1
6	cellular	MP:0005384	10.34	APC BRAF CTNNB1 ERCC2 IGF1 IL6
7	immune system	MP:0005387	10.31	APC BRAF CTNNB1 ERCC2 GNRH1 IGF1
8	renal/urinary system	MP:0005367	10.3	APC BRAF CTNNB1 GNRH1 IGF1 IL6
9	digestive/alimentary	MP:0005381	10.3	APC BRAF CTNNB1 GHRL GNRH1 IL6
10	adipose tissue	MP:0005375	10.27	APC BRAF ERCC2 GHRL IGF1 IL6
11	behavior/neurological	MP:0005386	10.27	APC BRAF CTNNB1 ERCC2 GHRL IL6
12	reproductive system	MP:0005389	10.27	APC BRAF CTNNB1 ERCC2 GNRH1 IGF1
13	normal	MP:0002873	10.26	APC BRAF CTNNB1 GHRL GNRH1 IGF1
14	liver/biliary system	MP:0005370	10.24	APC BRAF CTNNB1 GNRH1 IL6 INS
15	pigmentation	MP:0001186	10.22	APC BRAF CTNNB1 ERCC2 KRT14 LEF1
16	cardiovascular system	MP:0005385	10.22	APC BRAF CTNNB1 IGF1 IL6 INS
17	muscle	MP:0005369	10.19	APC BRAF CTNNB1 IGF1 IL6 INS
18	skeleton	MP:0005390	10.13	APC BRAF CTNNB1 ERCC2 GNRH1 IGF1
19	hearing/vestibular/ear	MP:0005377	10.1	APC BRAF CTNNB1 IGF1 KRT14 POU1F1
20	craniofacial	MP:0005382	10.05	APC BRAF CTNNB1 KRT14 LEF1 POU1F1
21	respiratory system	MP:0005388	10.01	BRAF CTNNB1 IGF1 IL6 KRT14 LEPR
22	hematopoietic system	MP:0005397	10	APC BRAF CTNNB1 ERCC2 GNRH1 IGF1
23	vision/eye	MP:0005391	9.96	APC BRAF CTNNB1 ERCC2 IL6 INS
24	mortality/aging	MP:0010768	9.83	APC BRAF CTNNB1 ERCC2 IGF1 IL6
25	integument	MP:0010771	9.44	APC BRAF CTNNB1 ERCC2 GNRH1 IGF1

Sources

Drugs & Therapeutics for Craniopharyngioma

Drugs for Craniopharyngioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 70)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Prednisone

Approved, Vet_approved

Phase 4

53-03-2

5865

Hydrocortisone succinate

Approved

Phase 4

2203-97-6

3643

Hydrocortisone acetate

Approved, Vet_approved

Phase 4

50-03-3

Hydrocortisone

Approved, Vet_approved

Phase 4

50-23-7

3640 5754

Antineoplastic Agents, Hormonal

Phase 4

Hormones

Phase 4

Hormone Antagonists

Phase 4

glucocorticoids

Phase 4

Anti-Inflammatory Agents

Phase 4

Anesthetics

Phase 4

Hydrocortisone 17-butyrate 21-propionate

Phase 4

Diazoxide

Approved

Phase 3

364-98-7

3019

Exenatide

Approved, Investigational

Phase 3

141758-74-9

45588096

Glucagon

Approved

Phase 3

16941-32-5

16133228 16186314

Antihypertensive Agents

Phase 3

Vasodilator Agents

Phase 3

Hypoglycemic Agents

Phase 3

Glucagon-Like Peptide 1

Phase 3

Incretins

Phase 3

Anti-Obesity Agents

Phase 3

Metformin

Approved

Phase 2

1115-70-4, 657-24-9

4091

Irinotecan

Approved, Investigational

Phase 2

97682-44-5, 100286-90-6

60838

Oxytocin

Approved, Vet_approved

Phase 2

50-56-6

439302 53477758

Nivolumab

Approved

Phase 2

946414-94-4

Trametinib

Approved

Phase 2

871700-17-3

11707110

Dabrafenib

Approved, Investigational

Phase 2

1195765-45-7

44462760

Vemurafenib

Approved

Phase 2

918504-65-1

42611257

Memantine

Approved, Investigational

Phase 2

41100-52-1, 19982-08-2

4054

Dopamine

Approved

Phase 2

62-31-7, 51-61-6

681

Peginterferon alfa-2b

Approved

Phase 2

215647-85-1, 99210-65-8

Racemethionine

Approved, Experimental, Investigational, Nutraceutical

Phase 2

59-51-8, 63-68-3, 348-67-4

6137

Insulin, Globin Zinc

Phase 2

Insulin

Phase 2

Angiogenesis Inhibitors

Phase 2

CKD732

Phase 2

topoisomerase I inhibitors

Phase 2

Immune Checkpoint Inhibitors

Phase 2

Antineoplastic Agents, Immunological

Phase 2

Protein Kinase Inhibitors

Phase 2

Fluorodeoxyglucose F18

Phase 2

Neurotransmitter Agents

Phase 2

Dopamine Agents

Phase 2

Antiparkinson Agents

Phase 2

Excitatory Amino Acid Antagonists

Phase 2

Antiviral Agents

Phase 2

Anti-Infective Agents

Phase 2

Vorinostat

Approved, Investigational

Phase 1

149647-78-9

5311

Bortezomib

Approved, Investigational

Phase 1

179324-69-7

387447 93860

Lenograstim

Approved, Investigational

Phase 1

135968-09-1

Temozolomide

Approved, Investigational

Phase 1

85622-93-1

5394

Interventional clinical trials:

(show all 50)

#	Name	Status	NCT ID	Phase	Drugs
1	Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions	Unknown status	NCT02190994	Phase 4	Hydrocortisone;Prednisone
2	Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial	Unknown status	NCT00517959	Phase 3
3	Multicentre Double-blind Randomized Clinical Trial Assessing Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy	Completed	NCT02860923	Phase 3	Exenatide;Placebo
4	Clinical Assessment of the Treatment With Diazoxide in Children Suffering From Obesity and Hyperinsulinemia Secondary to Surgery of Hypothalamic-pituitary Lesions	Completed	NCT00306683	Phase 3	DIAZOXIDE
5	Combined Diazoxide and Metformin Therapy in Children With Hypothalamic Obesity Secondary to Craniopharyngioma: A Pilot Study	Completed	NCT00892073	Phase 2	Diazoxide;Metformin
6	Phase II Study on the Management of Pediatric Craniopharyngioma by a Combination of Partial Surgical Resection, and Protontherapy	Completed	NCT02842723	Phase 2
7	Randomized, Double-Blind, Placebo Controlled, Phase 2a Trial of ZGN-440 (Subcutaneous Beloranib in Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Obese Subjects With Hypothalamic Injury to Evaluate Weight Reduction and Safety Over 4 Weeks Followed by an Optional 4-Week Open-Label Extension	Completed	NCT02063295	Phase 2	ZGN-440 sterile diluent;ZGN-440 for injectable suspension
8	Phase II Trial of Irinotecan in Children With Refractory Solid Tumors	Completed	NCT00004078	Phase 2	irinotecan hydrochloride
9	Effects of Exenatide on Body Weight in Patients With Hypothalamic Obesity	Completed	NCT01484873	Phase 2	Exenatide
10	Intranasal Oxytocin to Promote Weight Loss in Children, Adolescents, and Adults With Brain Tumors and Hypothalamic Obesity Syndrome	Completed	NCT02849743	Phase 2	Syntocinon;Placebo (for Syntocinon)
11	Nivolumab and DAY101 for the Treatment of Newly Diagnosed or Recurrent Craniopharyngioma in Children and Young Adults	Recruiting	NCT05465174	Phase 2	Nivolumab;DAY101
12	A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection	Recruiting	NCT02792582	Phase 2
13	Neoadjuvant and Postoperative Treatment With Dabrafenib and Trametinib in BRAF Mutated Papillary Craniopharyngioma	Recruiting	NCT05525273	Phase 2	Oral dabrafenib and trametinib
14	Methionine PET/CT Studies In Patients With Cancer	Recruiting	NCT00840047	Phase 2	Methionine
15	Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas	Recruiting	NCT03224767	Phase 2	Vemurafenib;Cobimetinib
16	A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection	Active, not recruiting	NCT01419067	Phase 2	^1^8F-fluorodeoxyglucose;^1^1C-methionine
17	Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors: A Pilot Study	Active, not recruiting	NCT03194906	Phase 2	Memantine
18	Phase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (Tocilizumab) for the Treatment of Progressive/Recurrent Pediatric Adamantinomatous Craniopharyngioma	Not yet recruiting	NCT05233397	Phase 2	Tocilizumab
19	Phase 2 Study of the MEK Inhibitor MEKTOVI® (Binimetinib) for the Treatment of Pediatric Adamantinomatous Craniopharyngioma	Not yet recruiting	NCT05286788	Phase 2	Binimetinib Oral Tablet [Mektovi]
20	Phase II Study of Peginterferon Alfa-2b (Sylatron) for Pediatric Patients With Unresectable or Recurrent Craniopharyngioma	Terminated	NCT01964300	Phase 2
21	Phase I Pilot Study of Stereotaxic Radiosurgery in Patients With Intracranial Neoplasms	Completed	NCT00019578	Phase 1
22	A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas	Completed	NCT00994500	Phase 1	vorinostat;bortezomib
23	Phase I Trial of Temozolomide and O6-Benzylguanine in Pediatric Patients With Recurrent Brain Tumors	Completed	NCT00052780	Phase 1	O6-benzylguanine;temozolomide
24	A Phase I Trial of CC-5013 (Lenalidomide) in Pediatric Patients With Recurrent or Refractory Primary CNS Tumors	Completed	NCT00100880	Phase 1	lenalidomide
25	Phase I Study of Cilengitide (EMD 121974) in Children With Refractory Brain Tumors	Completed	NCT00063973	Phase 1	cilengitide
26	A Phase I Study of SAHA and Temozolomide in Children With Relapsed or Refractory Primary Brain or Spinal Cord Tumors	Completed	NCT01076530	Phase 1	vorinostat;temozolomide
27	A PHASE 1 STUDY OF ISPINESIB (SB-715992) IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY SOLID TUMORS	Completed	NCT00363272	Phase 1	ispinesib
28	A Phase I Study of ABT-888, an Oral Inhibitor of Poly (ADP-Ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	Completed	NCT00946335	Phase 1	veliparib;temozolomide
29	A PHASE I STUDY OF DEPSIPEPTIDE (NSC#630176, IND# 51810) IN PEDIATRIC PATIENTS WITH REFRACTORY SOLID TUMORS AND LEUKEMIAS	Completed	NCT00053963	Phase 1	romidepsin
30	Phase 1 Trial of RO4929097 in Combination With Standard Radiotherapy and Temozolomide for Newly Diagnosed Malignant Glioma: A Pharmacokinetic and Pharmacodynamic Study	Completed	NCT01119599	Phase 1	Gamma-Secretase Inhibitor RO4929097;Temozolomide
31	Microenvironment: Imaging/Implications in Brain Tumors; A Preliminary Investigation of the Biodistribution of [F-18]-EF5 in Patients With Brain Tumors	Terminated	NCT00110032	Phase 1	EF5
32	A PHASE 1/2 STUDY OF RO4929097, AN ORAL SMALL MOLECULE INHIBITOR OF GAMMA-SECRETASE, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID OR CNS TUMORS, LYMPHOMA, OR T-CELL LEUKEMIA	Terminated	NCT01088763	Phase 1	gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
33	Tumor Classification and Its Application in Surgical Treatment of Craniopharyngioma	Unknown status	NCT00949156
34	Examining Sleep and Family Functioning in Pediatric Craniopharyngioma Using Ecological Momentary Assessment	Completed	NCT03330080
35	Weight Gain in Surgically Treated Adult-onset Craniopharyngioma	Completed	NCT01968603
36	Clinical Features and Risk Factors of Craniopharyngioma With Tumoral Hemorrhage	Completed	NCT04937335
37	Prospective, Multi-Center Survey Study of Children and Adolescents With Craniopharyngioma	Completed	NCT00258453
38	Social Participation After Childhood Craniopharyngioma	Completed	NCT03139526
39	Intraoperative Use of a MR Tomography System Combined With Neuronavigation - Analysis of the Craniopharyngioma Subgroup ("Intraoperative Nutzung Eines Kernspintomographie-Systems in Direkter Kopplung Mit Einem Neuronavigations-System")	Completed	NCT01206543
40	KRANIOPHARYNGEOM 2007 - Multicenter Prospective Study of Children and Adolescents With Craniopharyngioma	Completed	NCT01272622
41	Cross Sectional Study of Sleep-wake and Melatonin Patterns in Patients Treated for Craniopharyngiomas Compared to Matched Controls	Completed	NCT01881854
42	A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens	Completed	NCT00919750
43	KRANIOPHARYNGEOM Registry 2019 Multicenter Registry for Patients With Childhood-onset Craniopharyngioma, Xanthogranuloma, Cysts of Rathke's Pouch, Meningioma, Pituitary Adenoma, Arachnoid Cysts	Recruiting	NCT04158284
44	A Phase 0/Feasibility Trial of Tocilizumab in Children and Adolescents With Newly- Diagnosed or Recurrent/Progressive Adamantinomatous Craniopharyngioma	Recruiting	NCT03970226	Early Phase 1	Tocilizumab
45	Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology	Recruiting	NCT04648462
46	A Prospective Longitudinal Quality of Life Study in Patients Undergoing Endoscopic Endonasal Skull Base Surgery	Recruiting	NCT04087902
47	Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers	Active, not recruiting	NCT02162732
48	Advancing Treatment for Pediatric Craniopharyngioma: Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical Therapy	Enrolling by invitation	NCT03610906
49	Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors	Withdrawn	NCT02194452
50	Deep Brain Stimulation for Hypothalamic Obesity: A Surgical & Neuroimaging Study	Withdrawn	NCT03708913

Search NIH Clinical Center for Craniopharyngioma

Cochrane evidence based reviews: craniopharyngioma

Sources

Genetic Tests for Craniopharyngioma

Sources

Anatomical Context for Craniopharyngioma

Organs/tissues related to Craniopharyngioma:

MalaCards : Pituitary, Hypothalamus, Brain, Bone, Spinal Cord, Temporal Lobe, Pineal

Sources

Publications for Craniopharyngioma

Articles related to Craniopharyngioma:

(show top 50) (show all 3679)

#	Title	Authors	PMID	Year
1	Prospective enterprise-level molecular genotyping of a cohort of cancer patients. ⁵	MacConaill LE...Lindeman NI	25157968	2014
2	Novel immunohistochemical markers in the diagnosis of nonglial tumors of nervous system. ⁵³ ⁶²	Takei H...Powell SZ	20179436	2010
3	The differential diagnosis of central nervous system tumors: a critical examination of some recent immunohistochemical applications. ⁵³ ⁶²	Edgar MA...Rosenblum MK	18318590	2008
4	Expression of human MCM6 and DNA Topo II alpha in craniopharyngiomas and its correlation with recurrence of the tumor. ⁵³ ⁶²	Xu J...Wang X	17410335	2007
5	Acquired prolactin deficiency in patients with disorders of the hypothalamic-pituitary axis. ⁵³ ⁶²	Toledano Y...Shimon I	17556861	2007
6	[Expression of minichromosome maintenance protein 6 in craniopharyngioma and its correlation with prognosis]. ⁵³ ⁶²	Xu JG...Wang XS	17294730	2007
7	Mutation in exon 7 of PTCH deregulates SHH/PTCH/SMO signaling: possible linkage to WNT. ⁵³ ⁶²	Musani V...Levanat S	16596257	2006
8	Hypersomnolence and increased REM sleep with low cerebrospinal fluid hypocretin level in a patient after removal of craniopharyngioma. ⁵³ ⁶²	Tachibana N...Nishino S	16084764	2005
9	Expression and growth dependency of the insulin-like growth factor I receptor in craniopharyngioma cells: a novel therapeutic approach. ⁵³ ⁶²	Ulfarsson E...Girnita L	16000560	2005
10	Beta-catenin mutations in craniopharyngiomas and pituitary adenomas. ⁵³ ⁶²	Oikonomou E...Adams EF	15980970	2005
11	Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region. ⁵³ ⁶²	Buslei R...Fahlbusch R	15891929	2005
12	The clinical, metabolic and endocrine features and the quality of life in adults with childhood-onset craniopharyngioma compared with adult-onset craniopharyngioma. ⁵³ ⁶²	Kendall-Taylor P...Verhelst J	15817911	2005
13	Possible linkage between specific histological structures and aberrant reactivation of the Wnt pathway in adamantinomatous craniopharyngioma. ⁵³ ⁶²	Kato K...Tanaka Y	15221941	2004
14	Beta-catenin mutations are frequent in calcifying odontogenic cysts, but rare in ameloblastomas. ⁵³ ⁶²	Sekine S...Hirohashi S	14578169	2003
15	Growth without growth hormone. ⁵³ ⁶²	Phillip M...Lazar L	12510977	2002
16	Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations. ⁵³ ⁶²	Sekine S...Hirohashi S	12466115	2002
17	Differential expression of cytokeratins 8 and 20 distinguishes craniopharyngioma from rathke cleft cyst. ⁵³ ⁶²	Xin W...McKeever PE	12296753	2002
18	Craniopharyngioma: a case report and comparative galectin histochemical analysis. ⁵³ ⁶²	Plzak J...Gabius HJ	12495217	2002
19	Pseudotumor of the pituitary due to PROP-1 deletion. ⁵³ ⁶²	Teinturier C...Bougneres PF	11822586	2002
20	A study of the growth-promoting and metabolic effects of growth hormone (GH) in a patient with the "growth without GH" syndrome. ⁵³ ⁶²	Pavlou M...Papadopoulou ZL	11735238	2001
21	Different keratin profiles in craniopharyngioma subtypes and ameloblastomas. ⁵³ ⁶²	Tateyama H...Eimoto T	11770017	2001
22	The use of insulin-like growth factor 1 reference values for the diagnosis of growth hormone deficiency in prepubertal children. ⁵³ ⁶²	Bussieres L...Brauner R	10848878	2000
23	A boy with normal growth in spite of growth hormone deficiency after resection of a suprasellar teratoma. ⁵³ ⁶²	Araki K...Hiroi M	10890195	2000
24	Somatostatin receptor tumor imaging (Tc 99m P829) in pituitary adenoma. ⁵³ ⁶²	Chiewvit S...Ratanamart V	10659562	1999
25	Serum IGF-I and IGFBP-3 concentrations do not accurately predict growth hormone deficiency in children with brain tumours. ⁵³ ⁶²	Weinzimer SA...Moshang T	10469014	1999
26	The prevalence of severe growth hormone deficiency in adults who received growth hormone replacement in childhood [see comment]. ⁵³ ⁶²	Nicolson A...Shalet SM	8729528	1996
27	Effective use of magnetic resonance imaging in the assessment of children with possible growth hormone deficiency. ⁵³ ⁶²	Frindik JP...Pihoker C	15251557	1996
28	Could craniopharyngiomas produce pituitary hormones? ⁵³ ⁶²	Szeifert GT...Pasztor E	8098858	1993
29	Discontinuation of growth hormone therapy in growth-hormone-deficient patients: assessment of body fat mass using bioelectrical impedance. ⁵³ ⁶²	Colle M...Auzerie J	8314202	1993
30	Pulsatile prolactin secretion in hyperprolactinemia due to presumed pituitary stalk interruption. ⁵³ ⁶²	Samuels MH...Ridgway EC	1955511	1991
31	Demonstration of insulin-like growth factors I, II and heterogeneous insulin-like growth factor binding proteins in the cyst fluid of patients with craniopharyngioma. ⁵³ ⁶²	Zumkeller W...Hall K	1719442	1991
32	Extended endoscopic transsphenoidal approach for suprasellar craniopharyngiomas. ⁶²	Khalil W...Salle H	36460851	2022
33	Neuroendoscopic surgery combined with Ommaya reservoir placement for cystic craniopharyngiomas: 11 years of experience in a single institution. ⁶²	Chen A...Sun T	36469601	2022
34	Limited surgery and conformal photon radiation therapy for pediatric craniopharyngioma: long-term results from the RT1 protocol. ⁶²	Edmonston DY...Merchant TE	35556133	2022
35	Lesion network mapping of ectopic craniopharyngioma identifies potential cause of psychosis: a case report. ⁶²	Loh A...Mansouri A	36109364	2022
36	Combined pre-retrochiasmatic resection of third ventricle craniopharyngioma by endoscopic endonasal approach. ⁶²	Shou X...Wang Y	36074182	2022
37	Commentary: Resection of Giant Craniopharyngioma: Contending With Multiple Compartments and Myriad Perforating Arteries: 2-Dimensional Operative Video. ⁶²	Bocanegra-Becerra JE...Bendok BR	36251415	2022
38	Inhibition of integrated stress response protects against lipid-induced senescence in hypothalamic neural stem cells in adamantinomatous craniopharyngioma. ⁶²	Wang C...Liu Y	36454228	2022
39	Endoscopic endonasal surgery for craniopharyngioma in an 18-month-old boy. ⁶²	Tian Y...Zheng S	35717300	2022
40	Natural pregnancy after gross total resection of a large craniopharyngioma with hypothalamic involvement: a case report. ⁶²	Lin D...Zhou Z	34406611	2022
41	Clinical, Radiographic and Histopathological Analysis of Craniopharyngiomas and Ameloblastomas: A Systematic Review. ⁶²	da Silva LAM...Santos PPA	35920974	2022
42	Posterior hypothalamic involvement on pre-operative MRI predicts hypothalamic obesity in craniopharyngiomas. ⁶²	Rachmasari KN...Dobri GA	36462067	2022
43	Endocrine outcomes after limited surgery and conformal photon radiation therapy for pediatric craniopharyngioma: Long-term results from the RT1 protocol. ⁶²	Merchant TE...Lustig RH	35481829	2022
44	Outcomes of endoscopic endonasal resection of pediatric craniopharyngiomas. ⁶²	Patel TD...Palmer JN	35485414	2022
45	Multidisciplinary Management of Craniopharyngiomas in Children: A Single Center Experience. ⁶²	Del Baldo G...Carai A	36359587	2022
46	Minimally invasive endoscopic approaches to pediatric skull base pathologies. ⁶²	Yu S...Evans JJ	36206699	2022
47	Systemic inflammation caused by an intracranial mesenchymal tumor with a EWSR1::CREM fusion presenting associated with IL-6/STAT3 signaling. ⁶²	Hojo K...Nishikomori R	36328767	2022
48	A Latent Profile Analysis of Sleep, Anxiety, and Mood in Youth with Craniopharyngioma. ⁶²	Witcraft SM...Crabtree VM	34719997	2022
49	Safety and Efficacy of Pediatric Growth Hormone Therapy: Results From the Full KIGS Cohort. ⁶²	Maghnie M...Grimberg A	36102184	2022
50	The importance of preserving the superior hypophyseal artery infundibular branch in craniopharyngioma surgery. ⁶²	Sasaki H...Saito R	36355231	2022

Sources

Genes for Craniopharyngioma

Genes related to Craniopharyngioma (3 elite genes):

(show all 42)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	APC	APC Regulator Of WNT Signaling Pathway	Protein Coding	409.92	Pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
2	CTNNB1	Catenin Beta 1	Protein Coding	396.04	Causative somatic mutation ⁵⁸ Likely pathogenic ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	24413733 25157968 15891929 (more) 20128632 15221941 16596257 18540944 18318590 15980970 12466115 14578169 20179436
3	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	362.99	Causative somatic mutation ⁵⁸ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	24413733
4	ERCC2	ERCC Excision Repair 2, TFIIH Core Complex Helicase Subunit	Protein Coding	25	Likely pathogenic ⁵
5	IGF1	Insulin Like Growth Factor 1	Protein Coding	20.76	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10848878 15817911 10372703 (more) 1719442 10469014 8314202 16000560
6	MCM6	Minichromosome Maintenance Complex Component 6	Protein Coding	20.28	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17294730 17410335
7	KRT8	Keratin 8	Protein Coding	17.62	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12296753 11770017
8	KRT14	Keratin 14	Protein Coding	15.01	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11770017
9	PRL	Prolactin	Protein Coding	14.12	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17556861 10659562 7627336 (more) 8098858 1955511
10	INS	Insulin	Protein Coding	13.56	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
11	GHRL	Ghrelin And Obestatin Prepropeptide	Protein Coding	13.28	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
12	TRH	Thyrotropin Releasing Hormone	Protein Coding	13.1	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
13	PROP1	PROP Paired-Like Homeobox 1	Protein Coding	12.96	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11822586
14	POU1F1	POU Class 1 Homeobox 1	Protein Coding	12.94	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
15	GNRH1	Gonadotropin Releasing Hormone 1	Protein Coding	12.42	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
16	LEPR	Leptin Receptor	Protein Coding	12.26	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
17	KRT7	Keratin 7	Protein Coding	12.26	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
18	SOX2	SRY-Box Transcription Factor 2	Protein Coding	12.22	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
19	IL6	Interleukin 6	Protein Coding	11.97	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
20	LEF1	Lymphoid Enhancer Binding Factor 1	Protein Coding	11.95	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
21	SOX9	SRY-Box Transcription Factor 9	Protein Coding	11.88	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
22	ENAM	Enamelin	Protein Coding	11.73	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
23	NR5A1	Nuclear Receptor Subfamily 5 Group A Member 1	Protein Coding	11.7	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
24	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	11.62	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
25	MMP20	Matrix Metallopeptidase 20	Protein Coding	11.56	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
26	GH1	Growth Hormone 1	Protein Coding	11.54	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15251557 8729528 10659562 (more) 12510977 8879991 8098858 11735238 12807508 10890195
27	CD274	CD274 Molecule	Protein Coding	11.5	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
28	KRT5	Keratin 5	Protein Coding	11.31	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
29	EPCAM	Epithelial Cell Adhesion Molecule	Protein Coding	11.3	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
30	BMP2	Bone Morphogenetic Protein 2	Protein Coding	11.12	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
31	CD276	CD276 Molecule	Protein Coding	10.99	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
32	MMP9	Matrix Metallopeptidase 9	Protein Coding	10.99	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
33	IGF1R	Insulin Like Growth Factor 1 Receptor	Protein Coding	10.97	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
34	IL1A	Interleukin 1 Alpha	Protein Coding	10.9	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
35	PDCD1	Programmed Cell Death 1	Protein Coding	10.89	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
36	PTTG1	PTTG1 Regulator Of Sister Chromatid Separation, Securin	Protein Coding	10.87	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
37	CXCL1	C-X-C Motif Chemokine Ligand 1	Protein Coding	10.77	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
38	SPP1	Secreted Phosphoprotein 1	Protein Coding	10.74	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
39	IDO1	Indoleamine 2,3-Dioxygenase 1	Protein Coding	10.73	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
40	ANXA2	Annexin A2	Protein Coding	10.71	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
41	KRT19	Keratin 19	Protein Coding	10.7	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
42	KRT18	Keratin 18	Protein Coding	10.69	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)

Sources

Variations for Craniopharyngioma

ClinVar genetic disease variations for Craniopharyngioma:

⁵ (show all 12)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	APC	NM_000038.6(APC):c.3183_3187del (p.Lys1061_Gln1062insTer)	DEL	Pathogenic	88913	rs587779352	GRCh37: 5:112174471-112174475 GRCh38: 5:112838774-112838778
2	CTNNB1	NM_001904.4(CTNNB1):c.100G>A (p.Gly34Arg)	SNV	Likely Pathogenic	376232	rs121913399	GRCh37: 3:41266103-41266103 GRCh38: 3:41224612-41224612
3	ERCC2	NM_000400.4(ERCC2):c.1361TCA[2] (p.Ile456del)	MICROSAT	Likely Pathogenic	620626	rs750123656	GRCh37: 19:45860740-45860742 GRCh38: 19:45357482-45357484
4	CTNNB1	NM_001904.4(CTNNB1):c.101G>T (p.Gly34Val)	SNV	Likely Pathogenic	17582	rs28931589	GRCh37: 3:41266104-41266104 GRCh38: 3:41224613-41224613
5	CTNNB1	NM_001904.4(CTNNB1):c.94G>T (p.Asp32Tyr)	SNV	Likely Pathogenic	17581	rs28931588	GRCh37: 3:41266097-41266097 GRCh38: 3:41224606-41224606
6	CTNNB1	NM_001904.4(CTNNB1):c.100G>C (p.Gly34Arg)	SNV	Likely Pathogenic	376233	rs121913399	GRCh37: 3:41266103-41266103 GRCh38: 3:41224612-41224612
7	TSC1	NM_000368.5(TSC1):c.1355G>C (p.Gly452Ala)	SNV	Uncertain Significance	411263	rs371093730	GRCh37: 9:135782201-135782201 GRCh38: 9:132906814-132906814
8	PTCH1	NM_000264.5(PTCH1):c.113G>A (p.Gly38Glu)	SNV	Uncertain Significance	216367	rs143494325	GRCh37: 9:98270531-98270531 GRCh38: 9:95508249-95508249
9	PTCH1	NM_000264.5(PTCH1):c.203G>A (p.Gly68Glu)	SNV	Uncertain Significance	620601	rs757430199	GRCh37: 9:98268880-98268880 GRCh38: 9:95506598-95506598
10	TSC1	NM_000368.5(TSC1):c.1231C>A (p.Leu411Ile)	SNV	Uncertain Significance	64790	rs397514840	GRCh37: 9:135785990-135785990 GRCh38: 9:132910603-132910603
11	NF1	NM_001042492.3(NF1):c.4836G>A (p.Arg1612=)	SNV	Uncertain Significance	457720	rs1555533268	GRCh37: 17:29652838-29652838 GRCh38: 17:31325820-31325820
12	SUFU	NM_016169.4(SUFU):c.839G>A (p.Arg280Gln)	SNV	Uncertain Significance	241089	rs145704867	GRCh37: 10:104356979-104356979 GRCh38: 10:102597222-102597222

Sources

Expression for Craniopharyngioma

Search GEO for disease gene expression data for Craniopharyngioma.

Sources

Pathways for Craniopharyngioma

Pathways related to Craniopharyngioma according to GeneCards Suite gene sharing:

(show all 30)

#	Super pathways	Score	Top Affiliating Genes
1	Signal Transduction ⁶⁶	13.15	TRH SOX2 LEPR LEF1 INS IL6
2	Nanog in Mammalian ESC Pluripotency ⁶⁴ Show member pathways 14-3-3 Induced Intracellular Signaling ⁶⁴ eNOS Signaling ⁶⁴ GSK3 Signaling ⁶⁴	13.11	SOX2 LEF1 IL6 IGF1 GNRH1 CTNNB1
3	Alzheimer's disease and miRNA effects ⁷⁴ Show member pathways Alzheimer's disease ⁷⁴	12.74	INS IL6 CTNNB1 BRAF APC
4	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.62	LEF1 IGF1 CTNNB1 BRAF APC
5	Malignant pleural mesothelioma ⁷⁴	12.52	LEF1 INS IL6 IGF1 CTNNB1 APC
6	Human Embryonic Stem Cell Pluripotency ⁶⁴ Show member pathways Factors Promoting Cardiogenesis in Vertebrates ⁶⁴	12.38	SOX2 LEF1 CTNNB1 APC
7	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.34	APC BRAF CTNNB1 IGF1 LEF1
8	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.24	IL6 IGF1 GNRH1 CTNNB1 BRAF APC
9	Wnt / Hedgehog / Notch ³	12.15	SOX2 LEF1 CTNNB1 APC
10	Peptide hormone metabolism ⁶⁶ Show member pathways Glycoprotein hormones ⁶⁶ Metabolism of Angiotensinogen to Angiotensins ⁶⁶ Metabolism of Angiotensinogen to Angiotensins ⁷⁴ Peptide hormone biosynthesis ⁶⁶ Synthesis, secretion, and deacylation of Ghrelin ⁶⁶ thyroid hormone biosynthesis ⁶¹	12.11	INS IGF1 GHRL CTNNB1
11	Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers ⁶⁵	11.96	SOX2 INS IL6 IGF1
12	Adipogenesis ⁷⁴	11.94	INS IL6 IGF1 CTNNB1
13	Colorectal Cancer Metastasis ⁶⁴	11.87	LEF1 IL6 CTNNB1 BRAF APC
14	DNA damage response (only ATM dependent) ⁷⁴	11.83	LEF1 CTNNB1 APC
15	Senescence and autophagy in cancer ⁷⁴	11.82	INS IL6 IGF1 BRAF
16	Mesenchymal Stem Cells and Lineage-specific Markers ⁶⁵	11.8	INS IL6 IGF1
17	Overlap between signal transduction pathways contributing to LMNA laminopathies ⁷⁴ Show member pathways Influence of laminopathies on Wnt signaling ⁷⁴	11.78	LEF1 CTNNB1 APC
18	Corticotropin-releasing hormone signaling pathway ⁷⁴	11.76	KRT14 CTNNB1 BRAF
19	Regulation of nuclear beta catenin signaling and target gene transcription ⁶¹	11.65	LEF1 CTNNB1 APC
20	Glucocorticoid receptor regulatory network ⁶¹	11.59	PRL POU1F1 KRT14 IL6
21	Prader-Willi and Angelman syndrome ⁷⁴	11.57	INS GNRH1 GHRL
22	Hair follicle development: cytodifferentiation - part 3 of 3 ⁷⁴	11.51	IGF1 LEF1 SOX2
23	Cardiac progenitor differentiation ⁷⁴	11.48	SOX2 INS IGF1
24	Endoderm differentiation ⁷⁴	11.47	SOX2 LEF1 CTNNB1 APC
25	Pluripotent stem cell differentiation pathway ⁷⁴	11.42	INS IL6 IGF1
26	Signaling events mediated by PTP1B ⁶¹	11.4	PRL LEPR INS
27	Nonalcoholic fatty liver disease ⁷⁴	11.39	LEPR INS IL6
28	Deactivation of the beta-catenin transactivating complex ⁶⁶	11.08	SOX2 LEF1 CTNNB1 APC
29	Regulation of Wnt / B-catenin signaling by small molecule compounds ⁷⁴	10.75	APC CTNNB1 LEF1
30	Antipsychotics Pathway (Metabolic Side Effects), Pharmacodynamics ⁶⁰	10.23	PRL LEPR INS GHRL

Sources

GO Terms for Craniopharyngioma

Biological processes related to Craniopharyngioma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of cell population proliferation	GO:0008284	10.2	PRL LEF1 INS IL6 IGF1 CTNNB1
2	positive regulation of gene expression	GO:0010628	10.15	LEF1 INS IL6 IGF1 CTNNB1 BRAF
3	negative regulation of apoptotic process	GO:0043066	10.1	BRAF CTNNB1 GHRL IGF1 IL6 LEF1
4	epithelial to mesenchymal transition	GO:0001837	9.91	CTNNB1 IGF1 LEF1
5	positive regulation of epithelial to mesenchymal transition	GO:0010718	9.88	CTNNB1 IL6 LEF1
6	positive regulation of cell differentiation	GO:0045597	9.76	SOX2 LEF1 INS CTNNB1
7	positive regulation of MAPK cascade	GO:0043410	9.4	SOX2 INS IL6 IGF1 GHRL CTNNB1
8	adenohypophysis development	GO:0021984	9.35	SOX2 PROP1 POU1F1
9	hair cycle process	GO:0022405	9.32	ERCC2 CTNNB1